Abstract
The introduction of nanotechnologies into medical applications requires nanomedicine stakeholders to understand and apply the process of open innovation, which is essential for translation to the clinic. In Europe, such translation from excellence of science is a major area of priority to the different member states and the European Commission in order to establish a profitable and industrial nanomedicine sector. The current regulatory landscape and procedures together with the scaling-up of manufacturing processes have been frequently highlighted as major business hurdles gravitating around translational issues and often unknown to or underestimated by academia and early stage development projects. Numerous initiatives are however being taken and communication and awareness amongst stakeholders is increasing, which is of good hope as nanomedicine is entering a turning point where its industrial and societal impact will be shaped. By gathering, analysing and confronting state of the art papers and reports in the field, this chapter aims to deliver a critical overview of the recent nanomedicine landscape and ecosystem.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BIO:
-
Biotechnology Industry Organisation
- CAGR:
-
Compound Annual Growth Rate
- EC:
-
European Commission
- EPO:
-
European Patent Office
- ESF:
-
European Science Foundation
- ETPN:
-
European Technology Platform on Nanomedicine
- EU:
-
European Union
- FDA:
-
Food and Drug Administration
- FP:
-
Framework Programme
- GCP:
-
Good Clinical Practice
- GDP:
-
Gross Domestic Product
- GMO:
-
Good Manufacturing Organisation
- GMP:
-
Good Manufacturing Practice
- IP:
-
Intellectual Property
- IPTS:
-
Institute for Prospective Technological Studies
- JRC:
-
Joint Research Centre
- NDDS:
-
New Drug Delivery Systems
- NIH:
-
National Institute for Health
- R&D:
-
Research and Development
- SME:
-
Small and Medium Enterprise
- VC:
-
Venture Capital
- WoS:
-
Web of Science
References
European Science Foundation (2005) Forward look on nanomedicine. http://www.nanopharmaceuticals.org/files/nanomedicine.pdf. Accessed 18 July 2013
European Technology Platform on Nanomedicine (2006) Strategic research agenda for nanomedicine. ftp://ftp.cordis.europa.eu/pub/nanotechnology/docs/nanomedicine_bat_en.pdf. Accessed 18 July 2013
Institut für Philosophie (2009) NanoMed round table extended report. http://www.philosophie.tu-darmstadt.de/media/institut_fuer_philosophie/diesunddas/nordmann/nanomed.pdf. Accessed 18 Dec 2013
European Technology Platform on Nanomedicine (2013) Contribution of nanomedicine to horizon 2020. http://www.etp-nanomedicine.eu/public/press-documents/publications/etpn-publications/etpn-white-paper-H2020. Accessed 18 Jan 2014
Wagner V, Hüsin B, Gaisser S, Bock AK (2008) Nanomedicine: drivers for development and possible impacts. http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id = 1745. Accessed 18 Jan 2014
Wagner V, Dullaart A, Bock A, Zweck A (2006) The emerging nanomedicine landscape. Nat Biotechnol 24(10):1211–1217
Hüsing B, Gaisser S (2006) Nanobiotechnology in the medical sector – drivers for development and possible impacts. http://www.isi.fraunhofer.de/isi-media/docs/t/de/publikationen/ISI_Nanobiomedicine_WP3_revised-290320061.pdf. Accessed 18 July 2013
Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013) The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1):1–14
Bionest Partners and LEEM (2006) Nanomedicine study. http://www.leem.org/sites/default/files/1425.pdf. Accessed 18 July 2013
EuroNanoMed (2009) Strategic agenda for EuroNanoMed. http://www.euronanomed.net/files/Strategic_Agenda_for_EuroNanoMed.pdf. Accessed 18 July 2013
BCC Research LLC (2012) Nanotechnology in medical applications: the global market. http://www.bccresearch.com/market-research/healthcare/nanotechnology-medical-applications-global-market-hlc069b.html. Accessed 18 July 2013
Hafner A, Lovrić J, Lakoš G, Pepić I (2014) Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomed 9:1005–1023
Harris E (2014) Industry update: the latest developments in therapeutic delivery. Ther Deliv 5(4):381–386
Lévy L (2014) Europe as leaders in nanomedicine: let’s go for it! Nanomedicine 9(4):389–391
Menaa F (2014) Global financial model for responsible research and development of the fast growing nanotechnology business. J Bus Financ Affairs 3(1):1–2
Bawa R (2005) Will the nanomedicine “patent land grab” thwart commercialization? Nanomedicine 1(4):346–350
Bawa R, Bawa SR, Maebius S, Flynn T, Wei C (2005) Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine 1(2):150–158
Scrip Insights (2010) Nanotechnology in Healthcare: Market outlook for applications, tools and materials, and 40 company profiles. http://www.reportlinker.com/p0180553-summary/Nanotechnology-in-Healthcare-Market-outlook-for-applications-tools-and-materials-and-40-company-profiles.html. Accessed 18 July 2013
Jackson MJ, Whitt MD, Handy RG, Robinson GM, Whitfield MD (2009) Commercialization of nanotechnologies: technology transfer from University Research Laboratories. In: Ahmed W, Jackson MJ (eds) Emerging nanotechnologies for manufacturing, 1st edn. Elsevier, Oxford, pp 251–260
Pisano GP (2010) The evolution of science-based business: innovation how we innovate. Ind Corp Change 19(2):465–482
LuxCapital (2003) The NanoTech ReportTM 2003: Investment overview and market research for nanotechnology (Volume II). http://www.altassets.net/pdfs/nanotechreportluxcapital.pdf. Accessed 18 July 2013
Brower A (2005) Report portrays nanotechnology as driver of reduced R&D costs. Biotechnol Healthc 2(2):19–20
Bawa R (2007) Patents and nanomedicine. Nanomedicine 2(3):351–374
Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968
EuroNanoBio (2010) Concept for a European infrastructure in nanobiotechnology. http://www.nanowerk.com/nanotechnology/reports/reportpdf/report131.pdf. Accessed 18 July 2013
Prescott C (2010) Regenerative nanomedicines: an emerging investment prospective? J R Soc Interface 7(6):S783–S787
Morigi V, Tocchio A, Pellegrinelli CB, Sakamoto JH, Arnone M, Tasciotti E (2012) Nanotechnology in medicine: from inception to market domination. J Drug Deliv. doi:10.1155/2012/389485
Wiek A, Gasser L, Siegrist M (2009) Systemic scenarios of nanotechnology: sustainable governance of emerging technologies. Futures 41(5):284–300
Global Industry Analysts Inc (2009) Nanomedicine – a global market report. http://www.strategyr.com/MCP-1482.asp. Accessed 18 Jan 2014
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Fontaine, O., Boskovic, B., Ge, Y. (2014). Nanomedicine as a Business Venture. In: Ge, Y., Li, S., Wang, S., Moore, R. (eds) Nanomedicine. Nanostructure Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-2140-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-4614-2140-5_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-2139-9
Online ISBN: 978-1-4614-2140-5
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)